Ozempic belongs to a class of drugs called GLP-1 receptor agonists, also known as incretin mimetics or GLP-1 analogs. The active ingredient is semaglutide, a lab-modified version of a hormone your body naturally produces to regulate blood sugar. It’s FDA-approved for adults with type 2 diabetes, not as a standalone weight loss drug, though a higher-dose version of the same molecule (Wegovy) is approved specifically for weight management.
What GLP-1 Receptor Agonists Do
GLP-1 stands for glucagon-like peptide-1, a hormone released by your gut after you eat. It signals your pancreas to produce more insulin when blood sugar rises, while simultaneously telling your liver to stop pumping out extra glucose. Your body breaks down natural GLP-1 within minutes, so it doesn’t last long enough to be useful as a medication on its own.
GLP-1 receptor agonists like Ozempic are synthetic versions of this hormone, engineered to survive much longer in the body. Semaglutide shares 94% of its structure with human GLP-1 but includes three key chemical modifications that extend its half-life to roughly 165 hours, or about one week. One modification makes it resistant to the enzyme that normally chews up GLP-1 in minutes. Another attaches a fatty acid chain that lets the drug hitch a ride on albumin, a protein in your blood, keeping it circulating far longer. The result is a once-weekly injection that mimics what your gut hormone does naturally but sustains the effect around the clock.
Beyond blood sugar control, GLP-1 receptor agonists slow the rate at which your stomach empties food into the intestines. This is a major reason people feel fuller for longer and eat less. The drugs also act on appetite-regulating areas of the brain, reducing hunger and food cravings.
Other Drugs in the Same Class
Ozempic isn’t the only GLP-1 receptor agonist on the market. The class includes several medications with different dosing schedules and approved uses:
- Dulaglutide (Trulicity), a once-weekly injection for type 2 diabetes
- Liraglutide (Victoza), a daily injection for type 2 diabetes (also sold as Saxenda for weight management)
- Exenatide (Byetta, Bydureon BCise), available as a twice-daily or once-weekly injection
- Tirzepatide (Mounjaro), a once-weekly injection that targets both GLP-1 and a second incretin receptor called GIP
Semaglutide itself appears under multiple brand names. Ozempic is the diabetes formulation. Wegovy uses the same molecule at a higher maximum dose (2.4 mg versus Ozempic’s 2 mg) and is approved for weight management in adults and children 12 and older, for cardiovascular risk reduction in people with obesity and heart disease, and for a type of fatty liver disease called MASH. Rybelsus is an oral tablet form of semaglutide for type 2 diabetes.
What Ozempic Is Approved to Treat
The FDA has approved Ozempic for three specific uses, all in adults with type 2 diabetes. First, it’s used alongside diet and exercise to improve blood sugar control. Second, it’s approved to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in people with type 2 diabetes who already have established heart disease. Third, it’s approved to protect kidney function in adults with type 2 diabetes and chronic kidney disease, reducing the risk of sustained kidney decline and end-stage kidney disease.
Ozempic is not FDA-approved for weight loss, though doctors sometimes prescribe it off-label for that purpose. If weight management is the primary goal, Wegovy is the approved option. The distinction matters for insurance coverage: many insurers will only cover Ozempic with a type 2 diabetes diagnosis.
Cardiovascular Benefits Beyond Blood Sugar
One of the more significant findings about this drug class is its effect on heart health. In the SELECT trial, which studied semaglutide in patients with obesity and established cardiovascular disease (but without diabetes), the drug reduced major adverse cardiovascular events by 20%. This went beyond what blood sugar control alone would explain, suggesting GLP-1 receptor agonists have direct cardiovascular protective effects, likely related to reduced inflammation and improvements in blood vessel function.
How Ozempic Is Dosed
Ozempic is a once-weekly subcutaneous injection, meaning you inject it just under the skin, typically in the abdomen, thigh, or upper arm. The dosing follows a gradual ramp-up schedule. You start at 0.25 mg weekly for four weeks. That starting dose isn’t meant to control blood sugar; it’s designed to let your body adjust and minimize side effects. After four weeks, the dose increases to 0.5 mg. If blood sugar control still isn’t adequate after at least another four weeks, your prescriber may increase it to the maximum of 2 mg.
Common Side Effects
Digestive issues are by far the most common side effects. In a two-year clinical study, about 82% of people taking semaglutide experienced some form of gastrointestinal symptoms, compared with 54% on placebo. The most frequent complaints are nausea, diarrhea, constipation, stomach pain, bloating, and vomiting. These are generally mild to moderate and tend to improve after about 20 weeks of use, as the body adjusts and the drug’s effect on stomach emptying becomes less noticeable.
The gradual dose increase is specifically designed to reduce these early side effects. People who struggle with nausea at a given dose can sometimes stay at that level for longer before stepping up.
Who Should Not Take Ozempic
Ozempic carries a boxed warning, the FDA’s most serious label alert, regarding thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors. It’s not confirmed whether this risk applies to humans, but as a precaution, anyone with a personal or family history of medullary thyroid carcinoma or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2 should not use the drug. People who have had a serious allergic reaction to semaglutide or any inactive ingredient in the formulation are also unable to take it.